Navigation Links
Genetic variation increases risk of metabolic side effects in children on some antipsychotics
Date:1/24/2012

Researchers have found a genetic variation predisposing children to six-times greater risk of developing metabolic syndrome when taking second-generation anti-psychotic medications. Metabolic syndrome is a cluster of conditions that are risk factors for cardiovascular disease. The study showed a close association with two conditions in particular: high blood pressure and elevated fasting blood sugar levels, which is a precursor to diabetes. The research is published today in the medical research journal Translational Psychiatry.

"This is the first report of an underlying biological factor predisposing children to complications associated with second-generation anti-psychotic medication use," says Dr Dina Panagiotopoulos, study co-author, clinician scientist at the Child & Family Research Institute (CFRI), pediatric endocrinologist at BC Children's Hospital, and assistant professor, Department of Pediatrics, University of British Columbia (UBC).

"It's concerning because these children take medications to treat a chronic disease mental illness and then develop risk factors for a second chronic disease," says Dr. Angela Devlin, study co-author, CFRI scientist and assistant professor in the UBC Department of Pediatrics.

Second-generation anti-psychotics are prescribed to approximately 5500 children and youth in British Columbia for psychotic disorders, mood and anxiety disorders, attention deficit hyperactivity disorder, autism spectrum disorders, adjustment disorders and substance abuse. Of these medications, the two most commonly prescribed in B.C. are quetiapine (Seroquel) and risperidone (Risperdal).

For the study, researchers assessed 209 children who were inpatients between April 2008 and June 2011 at the Child & Adolescent Psychiatry Department at BC Children's Hospital, an agency of the Provincial Health Services Authority. Their average age was 13 years, and 105 of the children were treated with second-generation anti-psychotics while 112 did not use these drugs. DNA analysis showed that eight per cent of children from both groups had a genetic variation called C677T on the MTHFR gene. Children with the MTHFR C677T variant who used these medications were six-times more likely to have metabolic syndrome.

The researchers targeted the MTHFR C677T variant because it is known to be associated with metabolic syndrome in adults who have schizophrenia, and with cardiovascular disease in adults who don't have psychiatric illness.

Dr. Devlin and Dr. Panagiotopoulos say their discovery is an important step to preventing and managing metabolic complications associated with second-generation antipsychotic medications. It is critical to reduce these risks in childhood because adults with mental illness have a 19 per cent increased mortality rate that is largely due to cardiovascular disease risk.

The MTHFR gene is involved in metabolizing the B-vitamin folate.

"We now plan to assess B vitamin status and dietary intake in children who take these medications to gain a better understanding of this association," says Dr. Panagiotopoulos.


'/>"/>
Contact: Jennifer Kohm
jkohm@cfri.ca
604-875-2401
Child & Family Research Institute
Source:Eurekalert

Related medicine news :

1. New Genetic Clues to Breast Cancer?
2. Gladstone scientists identify genetic mechanism linked to congenital heart disease
3. Newborn screening program aims to help transform treatments for genetic diseases detected at birth
4. A genetic accelerator hits the gas on autoimmune diseases
5. UNC scientists collaborate to find first major genetic mutation associated with hereditary prostate cancer risk
6. TGen researchers map potential genetic origins, pathways of lung cancer in nonsmokers
7. Genetic predisposition to disease common in 2 supercentenarians: New study
8. Doubt Cast on Use of Genetic Test Before Plavix
9. Analysis does not support genetic test before use of anti-clotting drug
10. Key genetic error found in family of blood cancers
11. Researchers describe a new genetic program that converts static cells into mobile invasive cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: